Literature DB >> 17184854

In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPA.

Fabiana Dal Pozzo1, Graciela Andrei, Ilya Lebeau, James R Beadle, Karl Y Hostetler, Erik De Clercq, Robert Snoeck.   

Abstract

Acyclic nucleoside phosphonates (ANPs) and in particular (S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (HPMPC, cidofovir, CDV, Vistide) and its adenine counterpart (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine [(S)-HPMPA] are highly active against orf virus infections. This parapoxvirus commonly causes infection in sheep, goats, but also humans. Alkoxyalkyl esters of CDV have an increased oral bioavailability and are more active against orthopoxviruses than the parent compounds. In the present study, the potency of several alkoxyalkyl esters of CDV, cyclic cidofovir (cCDV) and (S)-HPMPA was evaluated against different orf virus isolates in two cell types, human embryonic lung (HEL) fibroblast and primary lamb keratinocytes. Each prodrug was at least 10-fold more active than its parent compound in both cell types. Of all the compounds tested, the (S)-HPMPA alkoxyalkyl esters showed the highest activity and selectivity against orf virus. Our results support the development of alkoxyalkyl esters of ANPs as antivirals not only for the treatment of complicated human orf lesions, but also in the therapy and prophylaxis of contagious ecthyma in sheep and goats.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17184854     DOI: 10.1016/j.antiviral.2006.11.010

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  10 in total

Review 1.  Prodrug strategies in ocular drug delivery.

Authors:  Megha Barot; Mahuya Bagui; Mitan R Gokulgandhi; Ashim K Mitra
Journal:  Med Chem       Date:  2012-07       Impact factor: 2.745

2.  Mutations conferring resistance to viral DNA polymerase inhibitors in camelpox virus give different drug-susceptibility profiles in vaccinia virus.

Authors:  Sophie Duraffour; Graciela Andrei; Dimitri Topalis; Marcela Krečmerová; Jean-Marc Crance; Daniel Garin; Robert Snoeck
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

Review 3.  Prodrugs of phosphonates and phosphates: crossing the membrane barrier.

Authors:  Andrew J Wiemer; David F Wiemer
Journal:  Top Curr Chem       Date:  2015

Review 4.  Phosphonate prodrugs: an overview and recent advances.

Authors:  Kenneth M Heidel; Cynthia S Dowd
Journal:  Future Med Chem       Date:  2019-07       Impact factor: 3.808

5.  Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art.

Authors:  Karl Y Hostetler
Journal:  Antiviral Res       Date:  2009-05       Impact factor: 5.970

6.  Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.

Authors:  Debra C Quenelle; Deborah J Collins; Bridgett P Herrod; Kathy A Keith; Julissa Trahan; James R Beadle; Karl Y Hostetler; Earl R Kern
Journal:  Antimicrob Agents Chemother       Date:  2007-09-10       Impact factor: 5.191

7.  Synthesis and early development of hexadecyloxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate.

Authors:  Karl Y Hostetler
Journal:  Viruses       Date:  2010-09-30       Impact factor: 5.818

Review 8.  Zoonotic Poxviruses Associated with Companion Animals.

Authors:  Danielle M Tack; Mary G Reynolds
Journal:  Animals (Basel)       Date:  2011-11-17       Impact factor: 2.752

9.  Pyrimidine 2,4-Diones in the Design of New HIV RT Inhibitors.

Authors:  Roberto Romeo; Daniela Iannazzo; Lucia Veltri; Bartolo Gabriele; Beatrice Macchi; Caterina Frezza; Francesca Marino-Merlo; Salvatore V Giofrè
Journal:  Molecules       Date:  2019-05-02       Impact factor: 4.411

10.  Poxviruses Bearing DNA Polymerase Mutations Show Complex Patterns of Cross-Resistance.

Authors:  Graciela Andrei; Pierre Fiten; Marcela Krečmerová; Ghislain Opdenakker; Dimitrios Topalis; Robert Snoeck
Journal:  Biomedicines       Date:  2022-03-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.